Stage Iii Melanoma clinical trials

Explore recruiting stage iii melanoma clinical trials.

Recruiting stage iii melanoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Stage Iii Melanoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Multicenter phase 3 trial comparing NeoADjuvant Ipilimumab + Nivolumab versus standard Adjuvant nivolumab in macroscopic stage III melanoma – NADINA

Netherlands, Italy, France, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

SWE-NEO: Swedish NeoAdjuvant Trial Comparing anti-PD-1 Monotherapy to Combined anti-CTLA-4/anti-PD-1 blockade in Resectable Stage III Melanoma

Sweden

Therapeutic confirmatory (Phase III) EU CTIS Study details

Assessment of Pharmacokinetic Similarity of FYB206 in Comparison with Keytruda in Resected Stage II or Stage III Melanoma Patients

Lithuania, Romania, Poland, Bulgaria, Estonia

Human Pharmacology (Phase I)- Bioequivalence Study EU CTIS Study details

S1404: A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma.

Ireland

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYMAKER-U02): Substudy 02C

France, Italy

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, double- blind Phase 3 trial of the EORTC Melanoma Group

Portugal, Sweden, Poland, Finland, Netherlands, Spain +7 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Stage Iii Melanoma trials by city

Stage Iii Melanoma in Toronto Stage Iii Melanoma in Vancouver Stage Iii Melanoma in Montreal Stage Iii Melanoma in Calgary Stage Iii Melanoma in Edmonton Stage Iii Melanoma in Ottawa Stage Iii Melanoma in Winnipeg Stage Iii Melanoma in Quebec City Stage Iii Melanoma in Hamilton Stage Iii Melanoma in Kitchener Stage Iii Melanoma in London Stage Iii Melanoma in Halifax Stage Iii Melanoma in New York Stage Iii Melanoma in Los Angeles Stage Iii Melanoma in Chicago Stage Iii Melanoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease